UBS Asset Management Americas Inc. lessened its holdings in MacroGenics, Inc. (NASDAQ:MGNX) by 6.9% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 371,569 shares of the biopharmaceutical company’s stock after selling 27,699 shares during the period. UBS Asset Management Americas Inc. owned about 1.01% of MacroGenics worth $6,506,000 as of its most recent SEC filing.
Several other hedge funds have also modified their holdings of the company. Vanguard Group Inc. raised its stake in shares of MacroGenics by 3.4% in the 1st quarter. Vanguard Group Inc. now owns 1,352,864 shares of the biopharmaceutical company’s stock valued at $25,163,000 after acquiring an additional 44,680 shares during the period. State Street Corp raised its stake in shares of MacroGenics by 20.0% in the 1st quarter. State Street Corp now owns 1,007,211 shares of the biopharmaceutical company’s stock valued at $18,732,000 after acquiring an additional 167,720 shares during the period. Teachers Advisors LLC raised its stake in shares of MacroGenics by 2.2% in the 2nd quarter. Teachers Advisors LLC now owns 322,309 shares of the biopharmaceutical company’s stock valued at $5,644,000 after acquiring an additional 6,859 shares during the period. Geode Capital Management LLC raised its stake in shares of MacroGenics by 4.4% in the 1st quarter. Geode Capital Management LLC now owns 260,670 shares of the biopharmaceutical company’s stock valued at $4,847,000 after acquiring an additional 10,983 shares during the period. Finally, Marshall Wace North America L.P. purchased a new position in shares of MacroGenics in the 1st quarter valued at $4,514,000. 84.47% of the stock is currently owned by institutional investors and hedge funds.
Shares of MacroGenics, Inc. (NASDAQ:MGNX) opened at 17.92 on Friday. MacroGenics, Inc. has a 1-year low of $14.36 and a 1-year high of $31.85. The stock’s market cap is $659.42 million. The company’s 50-day moving average is $17.61 and its 200 day moving average is $18.19.
MacroGenics (NASDAQ:MGNX) last posted its quarterly earnings data on Wednesday, August 2nd. The biopharmaceutical company reported ($1.14) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.05) by ($0.09). The firm had revenue of $1.70 million for the quarter, compared to the consensus estimate of $15.82 million. MacroGenics had a negative return on equity of 56.81% and a negative net margin of 1,216.51%. MacroGenics’s quarterly revenue was down 97.9% on a year-over-year basis. During the same period in the prior year, the company posted $1.12 earnings per share. Equities research analysts anticipate that MacroGenics, Inc. will post ($4.42) EPS for the current year.
TRADEMARK VIOLATION NOTICE: “UBS Asset Management Americas Inc. Cuts Stake in MacroGenics, Inc. (MGNX)” was first posted by Transcript Daily and is owned by of Transcript Daily. If you are reading this story on another site, it was copied illegally and reposted in violation of U.S. & international trademark and copyright law. The original version of this story can be viewed at https://transcriptdaily.com/2017/10/08/ubs-asset-management-americas-inc-cuts-stake-in-macrogenics-inc-mgnx.html.
MGNX has been the topic of a number of research reports. Wedbush reissued an “outperform” rating and issued a $44.00 target price on shares of MacroGenics in a research note on Monday, September 11th. Zacks Investment Research raised shares of MacroGenics from a “sell” rating to a “hold” rating and set a $19.00 target price on the stock in a research note on Tuesday, July 18th. Cowen and Company reissued a “buy” rating on shares of MacroGenics in a research note on Friday, August 4th. BidaskClub downgraded shares of MacroGenics from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 12th. Finally, Morgan Stanley cut their target price on shares of MacroGenics from $22.00 to $21.00 and set an “equal weight” rating on the stock in a research note on Monday, August 7th. Four research analysts have rated the stock with a sell rating, two have issued a hold rating and nine have given a buy rating to the stock. MacroGenics currently has a consensus rating of “Hold” and an average target price of $30.30.
MacroGenics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company develops therapeutic product candidates using its antibody-based technology platforms and also in collaboration with other biopharmaceutical companies.
Receive News & Ratings for MacroGenics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MacroGenics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.